{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:11:17Z","timestamp":1792185077583,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is a malignant proliferative disease of plasma cells, the incidence of which is increasing every year and remains incurable. The enzyme co-activator-associated arginine methyltransferase 1 (CARM1) is highly expressed in a variety of cancers, such as Hodgkin's lymphoma and acute myeloid leukemia, and CARM1 is closely associated with tumor cell proliferation. However, the role of CARM1 in MM has not been elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In this study, we found that CARM1 is overexpressed in MM and closely associated with poor prognosis in MM. CCK-8 and colony formation assays showed that the proliferation of MM cell lines was downregulated when CARM1 expression was knockdown by specific shRNA. Knockdown of CARM1 reduced the proportion of MM cell lines in the S phase and increased the proportion in G0\/G1 phase. RNA-seq analysis of the CARM1-KD cell line revealed that it was closely associated with apoptosis and activated the p53 pathway. CCK-8 and apoptosis results showed that CARM1 knockdown made MM cells more sensitive to standard-of-care drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides an experimental basis for elucidating the pathogenesis of multiple myeloma and searching for potential therapeutic targets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11033-023-08645-5","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T04:03:23Z","timestamp":1689912203000},"page":"7457-7469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Inhibition of CARM1 suppresses proliferation of multiple myeloma cells through activation of p53 signaling pathway"],"prefix":"10.1007","volume":"50","author":[{"given":"Lan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1527-0620","authenticated-orcid":false,"given":"Qiang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiePing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"issue":"5","key":"8645_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/jama.2021.25306","volume":"327","author":"J Silberstein","year":"2022","unstructured":"Silberstein J, Tuchman S, Grant SJ (2022) What Is Multiple Myeloma?[J]. JAMA 327(5):497","journal-title":"JAMA"},{"issue":"4","key":"8645_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/s41375-018-0362-z","volume":"33","author":"T Harding","year":"2019","unstructured":"Harding T, Baughn L, Kumar S et al (2019) The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies[J]. Leukemia 33(4):863\u2013883","journal-title":"Leukemia"},{"key":"8645_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2020.00001","volume":"10","author":"S Oliva","year":"2020","unstructured":"Oliva S, D\u2019Agostino M, Boccadoro M et al (2020) Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma[J]. Front Oncol 10:1","journal-title":"Front Oncol"},{"key":"8645_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12010015","volume":"12","author":"F Bonello","year":"2019","unstructured":"Bonello F, Mina R, Boccadoro M et al (2019) Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma[J]. Cancers (Basel) 12:1","journal-title":"Cancers (Basel)"},{"key":"8645_CR5","first-page":"12","volume":"11","author":"M Dagostino","year":"2019","unstructured":"Dagostino M, Bertamini L, Oliva S et al (2019) Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies[J]. Cancers (Basel) 11:12","journal-title":"Cancers (Basel)"},{"key":"8645_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1746-1596-8-129","volume":"8","author":"H Cheng","year":"2013","unstructured":"Cheng H, Qin Y, Fan H et al (2013) Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes[J]. Diagn Pathol 8:129","journal-title":"Diagn Pathol"},{"issue":"1","key":"8645_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1476-4598-12-40","volume":"12","author":"MB Davis","year":"2013","unstructured":"Davis MB, Liu X, Wang S et al (2013) Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity[J]. Mol Cancer 12(1):40","journal-title":"Mol Cancer"},{"issue":"47","key":"8645_CR8","doi-asserted-by":"publisher","first-page":"28408","DOI":"10.18632\/oncotarget.25400","volume":"9","author":"N Nakayama","year":"2018","unstructured":"Nakayama N, Sakashita G, Nariai Y et al (2018) Cancer-related transcription regulator protein NAC1 forms a protein complex with CARM1 for ovarian cancer progression[J]. Oncotarget 9(47):28408\u201328420","journal-title":"Oncotarget"},{"issue":"1","key":"8645_CR9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41467-018-03031-3","volume":"9","author":"S Karakashev","year":"2018","unstructured":"Karakashev S, Zhu H, Wu S et al (2018) CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity[J]. Nat Commun 9(1):631","journal-title":"Nat Commun"},{"issue":"4","key":"8645_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.molcel.2016.09.028","volume":"64","author":"YP Wang","year":"2016","unstructured":"Wang YP, Zhou W, Wang J et al (2016) Arginine Methylation of MDH1 by CARM1 Inhibits Glutamine Metabolism and Suppresses Pancreatic Cancer[J]. Mol Cell 64(4):673\u2013687","journal-title":"Mol Cell"},{"issue":"12","key":"8645_CR11","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1016\/j.celrep.2018.08.066","volume":"24","author":"XY Zhong","year":"2018","unstructured":"Zhong XY, Yuan XM, Xu YY et al (2018) CARM1 Methylates GAPDH to Regulate Glucose Metabolism and Is Suppressed in Liver Cancer[J]. Cell Rep 24(12):3207\u20133223","journal-title":"Cell Rep"},{"issue":"6","key":"8645_CR12","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.celrep.2013.11.025","volume":"5","author":"LP Vu","year":"2013","unstructured":"Vu LP, Perna F, Wang L et al (2013) PRMT4 Blocks Myeloid Differentiation by Assembling a Methyl-RUNX1-Dependent Repressor Complex[J]. Cell Rep (Cambridge) 5(6):1625\u20131638","journal-title":"Cell Rep (Cambridge)"},{"issue":"1","key":"8645_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/pathogens1010052","volume":"1","author":"S Leonard","year":"2012","unstructured":"Leonard S, Gordon N, Smith N et al (2012) Arginine Methyltransferases Are Regulated by Epstein-Barr Virus in B Cells and Are Differentially Expressed in Hodgkin\u2019s Lymphoma[J]. Pathogens 1(1):52\u201364","journal-title":"Pathogens"},{"issue":"8","key":"8645_CR14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.7150\/ijbs.19191","volume":"13","author":"S Li","year":"2017","unstructured":"Li S, Cheng D, Zhu B et al (2017) The Overexpression of CARM1 Promotes Human Osteosarcoma Cell Proliferation through the pGSK3\u03b2\/\u03b2-Catenin\/cyclinD1 Signaling Pathway[J]. Int J Biol Sci 13(8):976\u2013984","journal-title":"Int J Biol Sci"},{"issue":"6","key":"8645_CR15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.ccell.2018.05.007","volume":"33","author":"SM Greenblatt","year":"2018","unstructured":"Greenblatt SM, Man N, Hamard P et al (2018) CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis[J]. Cancer Cell 33(6):1111\u20131127","journal-title":"Cancer Cell"},{"issue":"26","key":"8645_CR16","doi-asserted-by":"publisher","first-page":"18480","DOI":"10.18632\/oncotarget.24883","volume":"9","author":"K Nakayama","year":"2018","unstructured":"Nakayama K, Szewczyk MM, Dela SC et al (2018) TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma[J]. Oncotarget 9(26):18480\u201318493","journal-title":"Oncotarget"},{"key":"8645_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"AE Drew","year":"2017","unstructured":"Drew AE, Moradei O, Jacques SL et al (2017) Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma[J]. Scie Rep 7:1","journal-title":"Scie Rep"},{"issue":"5\u20136","key":"8645_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1101\/gad.334516.119","volume":"34","author":"D Slade","year":"2020","unstructured":"Slade D (2020) PARP and PARG inhibitors in cancer treatment[J]. Genes Dev 34(5\u20136):360\u2013394","journal-title":"Genes Dev"},{"issue":"50","key":"8645_CR19","doi-asserted-by":"publisher","first-page":"33533","DOI":"10.1074\/jbc.273.50.33533","volume":"273","author":"FJ Oliver","year":"1998","unstructured":"Oliver FJ, De La Rubia G, Rolli V et al (1998) Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant[J]. J Biol Chem 273(50):33533\u201333539","journal-title":"J Biol Chem"},{"key":"8645_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1083\/jcb.202201159","volume":"221","author":"E Eskandari","year":"2022","unstructured":"Eskandari E, Eaves CJ (2022) Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis[J]. J Cell Biol 221:6","journal-title":"J Cell Biol"},{"key":"8645_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110048","volume":"126","author":"Y Xu","year":"2020","unstructured":"Xu Y, Zhou Q, Feng X et al (2020) Disulfiram\/copper markedly induced myeloma cell apoptosis through activation of JNK and intrinsic and extrinsic apoptosis pathways[J]. Biomed Pharmacother 126:110048","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"8645_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ccell.2016.06.013","volume":"30","author":"L Wang","year":"2016","unstructured":"Wang L, Zhao Z, Meyer MB et al (2016) CARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression and Metastasis[J]. Cancer Cell 30(1):179\u2013180","journal-title":"Cancer Cell"},{"issue":"7668","key":"8645_CR23","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, Decristo MJ, Watt AC et al (2017) CDK4\/6 inhibition triggers anti-tumour immunity[J]. Nature 548(7668):471\u2013475","journal-title":"Nature"},{"issue":"1","key":"8645_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lee JH, Lahuerta JJ et al (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study[J]. Leukemia 26(1):149\u2013157","journal-title":"Leukemia"},{"issue":"5","key":"8645_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/jnci\/djz159","volume":"112","author":"M Gao","year":"2020","unstructured":"Gao M, Bai H, Jethava Y et al (2020) Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma[J]. J Natl Cancer Inst 112(5):507\u2013515","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"8645_CR26","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.3892\/ijo.2016.3470","volume":"48","author":"T Takeda","year":"2016","unstructured":"Takeda T, Tsubaki M, Kino T et al (2016) Mangiferin enhances the sensitivity of human multiple myeloma cells to anticancer drugs through suppression of the nuclear factor kappaB pathway[J]. Int J Oncol 48(6):2704\u20132712","journal-title":"Int J Oncol"},{"issue":"2","key":"8645_CR27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00408-020-00324-7","volume":"198","author":"B Hu","year":"2020","unstructured":"Hu B, Li X, Chen L et al (2020) High Expression of CARM1 Inhibits Lung Cancer Progression by Targeting Tp53 by Regulating CTNNB1[J]. Lung 198(2):415\u2013422","journal-title":"Lung"},{"issue":"1","key":"8645_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12935-022-02522-0","volume":"22","author":"S Yang","year":"2022","unstructured":"Yang S, Zhang J, Chen D et al (2022) CARM1 promotes gastric cancer progression by regulating TFE3 mediated autophagy enhancement through the cytoplasmic AMPK-mTOR and nuclear AMPK-CARM1-TFE3 signaling pathways[J]. Cancer Cell Int 22(1):102","journal-title":"Cancer Cell Int"},{"issue":"15","key":"8645_CR29","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1073\/pnas.1114905109","volume":"109","author":"J Wu","year":"2012","unstructured":"Wu J, Xu W (2012) Histone H3R17me2a mark recruits human RNA polymerase-associated factor 1 complex to activate transcription[J]. Proc Natl Acad Sci U S A 109(15):5675\u20135680","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"8645_CR30","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/ncb3630","volume":"19","author":"F Liu","year":"2017","unstructured":"Liu F, Ma F, Wang Y et al (2017) PKM2 methylation by CARM1 activates aerobic glycolysis to promote tumorigenesis[J]. Nat Cell Biol 19(11):1358\u20131370","journal-title":"Nat Cell Biol"},{"issue":"1","key":"8645_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccr.2013.12.007","volume":"25","author":"L Wang","year":"2014","unstructured":"Wang L, Zhao Z, Meyer MB et al (2014) CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis[J]. Cancer Cell 25(1):21\u201336","journal-title":"Cancer Cell"},{"key":"8645_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.semcancer.2020.07.005","volume":"79","author":"MJ Duffy","year":"2022","unstructured":"Duffy MJ, Synnott NC, Grady OS et al (2022) Targeting p53 for the treatment of cancer[J]. Sem Cancer Biol 79:58\u201367","journal-title":"Sem Cancer Biol"},{"issue":"9","key":"8645_CR33","first-page":"1143","volume":"23","author":"A Scoumanne","year":"2008","unstructured":"Scoumanne A, Chen X (2008) Protein methylation: a new mechanism of p53 tumor suppressor regulation[J]. Histol Histopathol 23(9):1143\u20131149","journal-title":"Histol Histopathol"},{"issue":"6","key":"8645_CR34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.cell.2004.05.009","volume":"117","author":"W An","year":"2004","unstructured":"An W, Kim J, Roeder RG (2004) Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53[J]. Cell 117(6):735\u2013748","journal-title":"Cell"},{"issue":"15","key":"8645_CR35","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1128\/MCB.01747-07","volume":"28","author":"P Li","year":"2008","unstructured":"Li P, Yao H, Zhang Z et al (2008) Regulation of p53 target gene expression by peptidylarginine deiminase 4[J]. Mol Cell Biol 28(15):4745\u20134758","journal-title":"Mol Cell Biol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08645-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-023-08645-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08645-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T01:09:12Z","timestamp":1693098552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-023-08645-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["8645"],"URL":"https:\/\/doi.org\/10.1007\/s11033-023-08645-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the First Affiliated Hospital of Army Medical University. (No: (B) KY2022205).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}